Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1921 to 1935 of 8236 results

  1. Technologies to improve the detection of endometrial cancer

    Topic prioritisation

  2. Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441]

    In development Reference number: GID-TA11544 Expected publication date:  14 May 2026

  3. Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy [ID6509]

    In development Reference number: GID-TA11658 Expected publication date: TBC

  4. Avexitide for treating hypoglycaemia after bariatric surgery [TSID12233]

    Awaiting development Reference number: GID-TA11824 Expected publication date: TBC

  5. Mevrometostat with enzalutamide for treating hormone-relapsed metastatic prostate cancer after abiraterone acetate [TSID12239]

    Awaiting development Reference number: GID-TA11827 Expected publication date: TBC

  6. Odronextamab for treating relapsed or refractory follicular lymphoma [TSID12236]

    Awaiting development Reference number: GID-TA11829 Expected publication date: TBC

  7. CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic

    Topic prioritisation

  8. Emicizumab for preventing bleeding episodes in people with mild or moderate haemophilia A [ID5098]

    Topic prioritisation

  9. Artificial intelligence technologies for mammography: early value assessment

    Awaiting development Reference number: GID-HTE10062 Expected publication date: TBC

  10. Ferric citrate for managing iron and serum phosphorus levels in anaemia associated with chronic kidney disease [TSID12221]

    Topic prioritisation

  11. ID6611 Obesity, overweight - semaglutide (including review of TA875)

    Topic prioritisation

  12. Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [ID6627]

    Awaiting development Reference number: GID-TA11526 Expected publication date: TBC

  13. Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]

    In development Reference number: GID-TA11633 Expected publication date:  18 June 2026

  14. Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]

    In development Reference number: GID-TA11116 Expected publication date:  29 July 2026